LIFE SCIENCES | 卷:261 |
The functional role of long non-coding RNAs and their underlying mechanisms in drug resistance of non-small cell lung cancer | |
Review | |
Zhou, Hao1  Feng, Bing2  Abudoureyimu, Mubalake2  Lai, Yongting3  Lin, Xinrong2  Tian, Chuan2  Huang, Guichun2  Chu, Xiaoyuan2,3  Wang, Rui1,2  | |
[1] Nanjing Med Univ, Jinling Hosp, Dept Med Oncol, Nanjing, Peoples R China | |
[2] Nanjing Univ, Jinling Hosp, Sch Med, Dept Med Oncol, Nanjing, Peoples R China | |
[3] Southern Med Univ, Jinling Hosp, Nanjing Sch Clin Med, Dept Med Oncol, Nanjing, Peoples R China | |
关键词: Non-small cell lung cancer (NSCLC); Drug resistance; Long non-coding RNA (lncRNA); | |
DOI : 10.1016/j.lfs.2020.118362 | |
来源: Elsevier | |
【 摘 要 】
Background: Non-small cell lung cancer (NSCLC) is the most commonly diagnosed solid cancer and the main origin of cancer-related deaths worldwide. Current strategies to treat advanced NSCLC are based on a combined approach of targeted therapy and chemotherapy. But most patients will eventually get resistance to either chemotherapy or targeted therapy, leading to the poor prognosis. The mechanism of NSCLC drug resistance is inconclusive and is affected by multiple factors. Long non-coding RNAs (LncRNAs) are non-coding RNAs (ncRNAs) longer than 200 nucleotides. Recent studies show that lncRNAs are involved in many cellular physiological activities, including drug resistance of NSCLC. It is of great clinical significance to understand the specific mechanisms and the role of lncRNAs in it. Conclusions: Herein, we focus on the functional roles and the underlying mechanisms of lncRNAs in acquired drug resistance of NSCLC. LncRNAs have potential values as novel prognostic biomarkers and even therapeutic targets in the clinical management of NSCLC.
【 授权许可】
Free
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
10_1016_j_lfs_2020_118362.pdf | 1233KB | download |